LeukoGuard™ BC2

Pall Leukocyte Reduction Blood Cardioplegia Filter

- Improved protection against myocardial reperfusion injury*
- Removes activated neutrophils from blood cardioplegia
- Approx. 95 mL prime volume
- Flows up to 350 mL/min
- 1/4" connectors
Features and Benefits

The Pall Leukocyte Reduction Blood Cardioplegia Filter combines leukocyte reduction filtration media with a conventional 40 µm microemboli removal screen. The new low volume housing (95 mL) and improved media pleating technique allows easy application in modern blood cardioplegia systems.

- Reduces blood cardioplegia of circulating leukocytes, specifically activated neutrophils, which have been implicated as a major cause of myocardial reperfusion injury. (note: the removal efficiency will depend on total volume of blood cardioplegia delivered and the conditions which the blood cardioplegia is administered (i.e. flow, temperature, haemodilution etc).
- Incorporates a 40 µm screen capable of retaining gaseous and particulate microemboli.
- Designed to handle flow rates up to 350 mL/min, for a 3 litre throughput, over a wide range of cardioplegia administration practices.

* For clinical data please see clinical update or contact your Pall representative.

Ordering Information

<table>
<thead>
<tr>
<th>Reorder Code</th>
<th>Description</th>
<th>Packaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC2B</td>
<td>Pall LeukoGuard™ Blood Cardioplegia Filter - sterile with bypass</td>
<td>10/case</td>
</tr>
<tr>
<td>BC2NS</td>
<td>Pall LeukoGuard™ Blood Cardioplegia Filter (non-sterile)</td>
<td>50/box</td>
</tr>
<tr>
<td>FH1</td>
<td>Holder</td>
<td></td>
</tr>
</tbody>
</table>